• Mycobacterium tuberculosis and the response of its host
• 34 min
  1. The genetic structure of Mycobacterium tuberculosis - insights into genome organisation and evolution of the causative agent of tuberculosis

  • Dr. Roland Brosch
• 36 min
  2. The pathogenesis of tuberculosis

  • Dr. William R. Bishai
• 57 min
  3. Immune response and rational development of vaccines and biomarkers

  • Prof. Dr. Stefan H. E. Kaufmann
• 38 min
  4. Molecular mechanisms of drug resistance in M. tuberculosis

  • Dr. Daniela Cirillo
• The epidemiology of tuberculosis
• 40 min
  5. The basic epidemiology of tuberculosis (TB)

  • Dr. David Dowdy
• 34 min
  6. Global epidemiology of TB

  • Dr. Philippe Glaziou
• 48 min
  7. Social determinants of tuberculosis

  • Dr. Knut Lönnroth
• The control of tuberculosis
• 46 min
  8. Treatment of tuberculosis

  • Dr. Jean-Pierre Zellweger
• 32 min
  9. The End TB Strategy towards TB elimination 1

  • Dr. Mario Raviglione
• 52 min
  10. The End TB Strategy towards TB elimination 2

  • Dr. Mario Raviglione
• 38 min
  11. Financing TB care and control

  • Dr. Christopher Fitzpatrick
  • Dr. Andrea Pantoja
• 27 min
  12. Tuberculosis and COVID-19

  • Prof. Giovanni Battista Migliori
• 36 min
  13. Multidrug resistant tuberculosis (MDR-TB): an update

  • Dr. Simon Tiberi
• 49 min
  14. Impact of HIV on tuberculosis in the developing world and how to manage it

  • Prof. Anthony D. Harries
• 33 min
  15. Reaching the missing millions through public-private mix (PPM) for TB prevention and care

  • Ms. Hannah Monica Dias
• 39 min
  16. TB in children

  • Prof. Ben J. Marais
• 30 min
  17. Community engagement in tuberculosis care

  • Ms. Lana Syed
• 29 min
  18. India: the epicentre of global TB control

  • Dr. Madhukar Pai
• 23 min
  19. Community engagement in TB care

  • Dr. Haileyesus Getahun
• Research and development for new approaches in the control of tuberculosis
• 21 min
  20. Development of new regimens for tuberculosis

  • Dr. Zhenkun Ma
• 35 min
  21. Development, testing and introduction of new diagnostic tools for tuberculosis

  • Dr. Mark Perkins
• 69 min
  22. Pharmacometrics in tuberculosis

  • Prof. Charles A. Peloquin
• 29 min
  23. Extrapulmonary tuberculosis

  • Dr. Scott Heysell
• 27 min
  24. The role of surgery in tuberculosis management

  • Dr. Richard Zaleskis
• Archived Lectures *These may not cover the latest advances in the field
• 28 min
  25. The development of current treatments for tuberculosis

  • Dr. Andrew Nunn
• 47 min
  26. The pathogenesis of tuberculosis

  • Dr. William R. Bishai
• 34 min
  27. Basics of tuberculosis epidemiology

  • Prof. Frank Cobelens
• 40 min
  28. Drug resistance in tuberculosis and its public health management

  • Dr. Paul Nunn
• 57 min
  29. The international approach to the control of tuberculosis

  • Dr. Mario Raviglione
• 35 min
  30. Public-private mix for TB care and control

  • Dr. Mukund Uplekar

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. Contents
3. Definitions
4. Rationale for concern about MDR-TB
5. Drug resistance increases, treatment success fall
6. Managing a severe epidemic of resistance
7. The size & distribution of the MDR-TB epidemic
8. The global burden of TB 2010
9. Distribution of MDR among new TB cases
10. Distribution of MDR among previously treated TB
11. Estimated MDR-TB incidence rates, 2009
12. Highest % of MDR-TB among new cases
13. Time trends in TB and MDR-TB
14. Countries that reported XDR-TB by end Mar. 2011
15. Global strategies, plans and implementation
16. MDR & XDR- TB control strategic challenges
17. Indicators for PMDT
18. Funding increase but lower than planned
19. MDR-TB notified, projected & global targets
20. MDR-TB treatment enrolment targets 2011
21. DST coverage in 2010
22. Treatment success
23. National level planning and implementation
24. Guidance for MDR-TB management programmes
25. Why plan MDR-TB treatment programmes?
26. Essential principles of care for MDR-TB
27. Essential elements in planning TB control
28. Specific recommendations for PMDT (1)
29. Specific recommendations for PMDT (2)
30. Specific recommendations for PMDT (3)
31. Specific recommendations for PMDT (4)
32. Research gaps
33. Obstacles to MDR-TB management
34. Only few MDR-TB cases are diagnosed & treated
35. Conclusions
36. Policy background
37. References (1)
38. References (2)
39. Acknowledgements

Topics Covered

• Definition of common terms
• The rationale for addressing drug resistance
• The size and distribution of the drug resistance epidemic in TB
• Global level plans for addressing it
• National level plans and implementation
• Obstacles and conclusions
• Sources for further study of the policy background

Links

Series:

• Tuberculosis

Categories:

• Microbiology

Therapeutic Areas:

• Infectious Diseases
• Respiratory Diseases

Talk Citation

Publication History

• Published on February 28, 2013
• Archived on November 28, 2021

Financial Disclosures

• Dr. Paul Nunn has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.